Literature DB >> 23504323

Characterization of heparanase-induced phosphatidylinositol 3-kinase-AKT activation and its integrin dependence.

Anjum Riaz1, Neta Ilan, Israel Vlodavsky, Jin-Ping Li, Staffan Johansson.   

Abstract

Heparanase functions as a heparan sulfate-degrading enzyme and as a ligand for an unidentified signaling receptor(s). Here, several reactions involved in the activation of the PI3K-AKT pathway by latent heparanase were characterized. Protein suppression using specific siRNAs revealed that heparanase-induced phosphorylation of AKT at Ser-473 was RICTOR-mTOR-dependent, whereas ILK and PAK1/2 were dispensable. p110α was the PI3K catalytic isoform preferred by heparanase for AKT activation and cell proliferation because the p110α inhibitor YM024 blocked these processes. Heparanase-induced AKT phosphorylation was low in mouse embryonic fibroblast cells expressing a RAS interaction-defective p110α compared with wild type cells, indicating that RAS has an important role in the PI3K-AKT activation. The response to heparanase was also inefficient in suspension cultures of several cell lines, suggesting a requirement of integrins in this pathway. Adhesion via either αVβ3 or α5β1 promoted heparanase-induced AKT phosphorylation, and a stronger effect was seen when both integrins were engaged. Simultaneous inhibition of FAK and PYK2 using a chemical inhibitor, or suppression of their expression, inhibited heparanase-induced AKT activation and cell proliferation. Stimulation of cells with heparanase enhanced their resistance against oxidative stress- or growth factor starvation-induced apoptosis. These results demonstrate that there is an intimate cross-talk between the heparanase receptor(s) and integrins during induction of the prosurvival PI3K-AKT pathway by heparanase.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23504323      PMCID: PMC3636920          DOI: 10.1074/jbc.M112.435172

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

1.  Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice.

Authors:  Surbhi Gupta; Antoine R Ramjaun; Paula Haiko; Yihua Wang; Patricia H Warne; Barbara Nicke; Emma Nye; Gordon Stamp; Kari Alitalo; Julian Downward
Journal:  Cell       Date:  2007-06-01       Impact factor: 41.582

Review 2.  Cooperation between integrins and growth factor receptors in signaling and endocytosis.

Authors:  Johanna Ivaska; Jyrki Heino
Journal:  Annu Rev Cell Dev Biol       Date:  2011-06-10       Impact factor: 13.827

3.  Anchorage of VEGF to the extracellular matrix conveys differential signaling responses to endothelial cells.

Authors:  Tom T Chen; Alfonso Luque; Sunyoung Lee; Sean M Anderson; Tatiana Segura; M Luisa Iruela-Arispe
Journal:  J Cell Biol       Date:  2010-02-22       Impact factor: 10.539

4.  PI 3-kinase p110beta: a new target for antithrombotic therapy.

Authors:  Shaun P Jackson; Simone M Schoenwaelder; Isaac Goncalves; Warwick S Nesbitt; Cindy L Yap; Christine E Wright; Vijaya Kenche; Karen E Anderson; Sacha M Dopheide; Yuping Yuan; Sharelle A Sturgeon; Hishani Prabaharan; Philip E Thompson; Gregg D Smith; Peter R Shepherd; Nathalie Daniele; Suhasini Kulkarni; Belinda Abbott; Dilek Saylik; Catherine Jones; Lucy Lu; Simon Giuliano; Sascha C Hughan; James A Angus; Alan D Robertson; Hatem H Salem
Journal:  Nat Med       Date:  2005-04-17       Impact factor: 53.440

Review 5.  Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis.

Authors:  Neta Ilan; Michael Elkin; Israel Vlodavsky
Journal:  Int J Biochem Cell Biol       Date:  2006-07-06       Impact factor: 5.085

6.  The related adhesion focal tyrosine kinase is tyrosine-phosphorylated after beta1-integrin stimulation in B cells and binds to p130cas.

Authors:  A Astier; H Avraham; S N Manie; J Groopman; T Canty; S Avraham; A S Freedman
Journal:  J Biol Chem       Date:  1997-01-03       Impact factor: 5.157

7.  Focal adhesion kinase is upstream of phosphatidylinositol 3-kinase/Akt in regulating fibroblast survival in response to contraction of type I collagen matrices via a beta 1 integrin viability signaling pathway.

Authors:  Hong Xia; Richard Seonghun Nho; Judy Kahm; Jill Kleidon; Craig A Henke
Journal:  J Biol Chem       Date:  2004-05-27       Impact factor: 5.157

8.  Receptor-specific mechanisms regulate phosphorylation of AKT at Ser473: role of RICTOR in β1 integrin-mediated cell survival.

Authors:  Anjum Riaz; Kathrin Stephanie Zeller; Staffan Johansson
Journal:  PLoS One       Date:  2012-02-22       Impact factor: 3.240

9.  Heparanase expression is a prognostic indicator for postoperative survival in pancreatic adenocarcinoma.

Authors:  J Rohloff; J Zinke; K Schoppmeyer; A Tannapfel; H Witzigmann; J Mössner; C Wittekind; K Caca
Journal:  Br J Cancer       Date:  2002-04-22       Impact factor: 7.640

10.  PyK2 and FAK connections to p190Rho guanine nucleotide exchange factor regulate RhoA activity, focal adhesion formation, and cell motility.

Authors:  Yangmi Lim; Ssang-Taek Lim; Alok Tomar; Margaret Gardel; Joie A Bernard-Trifilo; Xiao Lei Chen; Sean A Uryu; Rafaela Canete-Soler; Jinbin Zhai; Hong Lin; William W Schlaepfer; Perihan Nalbant; Gary Bokoch; Dusko Ilic; Clare Waterman-Storer; David D Schlaepfer
Journal:  J Cell Biol       Date:  2008-01-14       Impact factor: 10.539

View more
  23 in total

Review 1.  Heparan Sulfate Proteoglycans as Relays of Neuroinflammation.

Authors:  Paul O'Callaghan; Xiao Zhang; Jin-Ping Li
Journal:  J Histochem Cytochem       Date:  2018-01-01       Impact factor: 2.479

2.  Heparanase promotes human gastric cancer cells migration and invasion by increasing Src and p38 phosphorylation expression.

Authors:  Xiu Mei Ma; Zhi Hua Shen; Zhi Yao Liu; Fang Wang; Ling Hai; Lin Tao Gao; Hai Sheng Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

Review 3.  Heparanase: From basic research to therapeutic applications in cancer and inflammation.

Authors:  Israel Vlodavsky; Preeti Singh; Ilanit Boyango; Lilach Gutter-Kapon; Michael Elkin; Ralph D Sanderson; Neta Ilan
Journal:  Drug Resist Updat       Date:  2016-10-06       Impact factor: 18.500

4.  Integrated Analysis Reveals the Gut Microbial Metabolite TMAO Promotes Inflammatory Hepatocellular Carcinoma by Upregulating POSTN.

Authors:  Yonglin Wu; Xingyu Rong; Miaomiao Pan; Tongyao Wang; Hao Yang; Xiejiu Chen; Zhenming Xiao; Chao Zhao
Journal:  Front Cell Dev Biol       Date:  2022-05-23

5.  Glycocalyx Disruption Triggers Human Monocyte Activation in Acute Heart Failure Syndromes.

Authors:  Olga G Grushko; Steven Cho; Ashley M Tate; Robert S Rosenson; David J Pinsky; Jacob M Haus; Scott L Hummel; Sascha N Goonewardena
Journal:  Cardiovasc Drugs Ther       Date:  2022-10-19       Impact factor: 3.947

6.  PI-88 inhibits postoperative recurrence of hepatocellular carcinoma via disrupting the surge of heparanase after liver resection.

Authors:  Bo-Yi Liao; Zheng Wang; Jie Hu; Wei-Feng Liu; Zao-Zhuo Shen; Xin Zhang; Lei Yu; Jia Fan; Jian Zhou
Journal:  Tumour Biol       Date:  2015-09-28

7.  Heparanase cooperates with Ras to drive breast and skin tumorigenesis.

Authors:  Ilanit Boyango; Uri Barash; Inna Naroditsky; Jin-Ping Li; Edward Hammond; Neta Ilan; Israel Vlodavsky
Journal:  Cancer Res       Date:  2014-06-26       Impact factor: 12.701

8.  Heparanase enhances myeloma progression via CXCL10 downregulation.

Authors:  U Barash; Y Zohar; G Wildbaum; K Beider; A Nagler; N Karin; N Ilan; I Vlodavsky
Journal:  Leukemia       Date:  2014-04-04       Impact factor: 11.528

9.  NK cell heparanase controls tumor invasion and immune surveillance.

Authors:  Eva M Putz; Alyce J Mayfosh; Kevin Kos; Deborah S Barkauskas; Kyohei Nakamura; Liam Town; Katharine J Goodall; Dean Y Yee; Ivan Kh Poon; Nikola Baschuk; Fernando Souza-Fonseca-Guimaraes; Mark D Hulett; Mark J Smyth
Journal:  J Clin Invest       Date:  2017-06-05       Impact factor: 14.808

Review 10.  Towards understanding the roles of heparan sulfate proteoglycans in Alzheimer's disease.

Authors:  Gan-lin Zhang; Xiao Zhang; Xiao-min Wang; Jin-Ping Li
Journal:  Biomed Res Int       Date:  2014-07-23       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.